Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

NCT06372496 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06372496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06372496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Active, not recruiting
Start date
April 16, 2024
Completion date
June 14, 2027
Enrollment
1,358 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

asthma